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Abstract
Aims Cardiac sarcoidosis (CS) and giant cell myocarditis (GCM) are inflammatory cardiomyopathies sharing histopathological
and clinical features. Their differentiation is difficult and susceptible of confusion and apparent mistakes. The possibility that
they represent different phenotypes of a single disease has been debated.
Methods and results We made a retrospective audit of 73 cases of GCM diagnosed in Finland since the late 1980s. All avail-
able histological material was reanalyzed as were other examinations pertinent to the distinction between GCM and CS. Find-
ing granulomas in or outside the heart was considered diagnostic of CS and exclusive of GCM. Altogether 45 of the 73 cases of
GCM (62%) were reclassified as CS. In all except one case, this was based on finding sarcoid granulomas that either had been
originally missed (n = 29) or misinterpreted (n = 11) or were found in additional posttransplant myocardial specimens (n = 3) or
samples of extracardiac tissue (n = 1) accrued over the disease course. Supporting the reclassification, patients relocated to the
CS group had less heart failure at presentation (prevalence 20% vs. 46%, P = 0.017) and better 1 year transplant-free survival
(82% vs. 45%, P = 0.011) than patients considered to represent true GCM.
Conclusions Recognizing granulomas in or outside the heart remains a challenge for the pathologist. Given that CS and GCM
are considered distinct diseases and granulomas exclusive of GCM, many cases of GCM, if thoroughly scrutinized, may need
reclassification as CS. However, whether CS and GCM are truly different entities or parts of a one-disease continuum has
not yet been conclusively settled.
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Introduction
The first reports of giant cell myocarditis (GCM) and cardiac
sarcoidosis (CS) date back to the early decades of the 20th
century.1,2 Still today, a hundred years later, clinicians remain
puzzled by their many unknowns like what are their respec-
tive causes and mechanisms and are they genuinely different
diseases or merely different segments of a single disease
spectrum. Both conditions have been attributed to T
lymphocyte-mediated autoimmune myocardial injury, and
they have many similarities in myocardial histopathology
and clinical manifestations.3–6 The studies by Litovsky et al.4
and Okura et al.6 at the turn of millennium seemed, however,
to establish GCM and CS as different disease entities. Myo-
cardial granulomas and fibrosis have since been taken as
the histologic hallmarks of CS while prominent necrosis and
a diffuse infiltrate of mixed inflammatory cells including mul-
tinuclear giant cells and eosinophils are considered peculiar
for GCM.3,6–8
We have in Finland a registry of patients diagnosed during
life with CS or GCM since the late 1980s.9 Recently, additional
cases diagnosed only at autopsy were identified and included
from the cause-of-death registry. In reanalyzing the autopsy
material, we found cases of CS mistaken for GCM.10 In a par-
allel case, we came across an explanted heart showing abun-
dant granulomas in a patient with a pretransplant diagnosis
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of GCM. In response, we decided to audit each GCM diagno-
sis in our registry. To that end, we reassessed the original di-
agnostic slides and any later myocardial biopsies as well as
samples of extracardiac tissue and other diagnostic studies.
The need to consider reclassification of GCM was surprisingly
high. Here, we detail the main causes for the apparent mis-
takes of CS for GCM but discuss also whether CS and GCM
could represent a one-disease continuum rather than two dif-
ferent entities.
Methods
The cases
Clinical registry
The Myocardial Inflammatory Diseases in Finland (MIDFIN)
study group is a cardiology research network maintaining a
nationwide registry of adult patients diagnosed with CS or
GCM since the late 1980s. The details of the registry are de-
scribed in our earlier publications.9,11,12 The data filed on in-
dividual patients include information about demographics,
cardiac manifestations, and associated diseases as well as re-
sults of diagnostic imaging and laboratory studies and treat-
ment with drugs and devices. All patients have been
followed-up in the hospitals of the MIDFIN research network,
and their outcome events including death, transplantation,
and life-threatening arrhythmias have been recorded. The
case was included as GCM in the registry if myocardial histol-
ogy showed myocyte injury with or without necrosis associ-
ated with an inflammatory infiltrate variably composed of
lymphocytes, histiocytes, eosinophils, and multinuclear GCs
without other explanations. The presence of unequivocal
non-necrotic granulomas was considered diagnostic of CS
and exclusive of GCM. All diagnoses had been made by two
cardiac pathologists one of whom (A.R.-S). is also authoring
the present work. At the end of 2015, the MIDFIN registry in-
cluded 50 cases of idiopathic GCM fulfilling the above criteria.
All except one of them could be included in the present work.
Cause-of-death registry
As described elsewhere,10 we recently screened the Finnish
cause-of-death registry to identify patients dying suddenly
out of hospital and diagnosed with CS or GCM only at au-
topsy. The registry files were available to us in digital format
from 1998 through 2015, and altogether, 820 605 death cer-
tificates were subjected to detailed screening.10 In all, 24 can-
didate cases of GCM were identified based on the
documentation of the primary cause of death as the ICD-10
codes I51.4 (myocarditis, unspecified) or I40 (acute myocardi-
tis) with the phrase ‘giant cell myocarditis’ in the text body of
the death certificate. The autopsies had been made by foren-
sic (21/24) or general (3/24) pathologists.
Methods of the audit
For the review of the 49 GCM cases from the MIDFIN registry,
we acquired for microscopy all slides and histologic material
still available from the original diagnostic myocardial biopsies
as well as any specimens available from follow-up biopsies or
explanted or autopsied hearts and any lifetime or autopsy
samples of extracardiac tissues. In cases of difficult-to-assess
myocardial histology, we made ancillary studies with immu-
nohistochemistry using the following antibodies: CD3 (clone:
2VG6, Ventana, Phoenix, AZ), CD4 (clone: SP35, Cell Marque),
CD8 (clone: 4B11, Novocastra), CD31 (clone: JC70A, Dako),
CD68 (clone: PG-M1, Dako), and PD-L1 (clone: SP142,
Abcam). In addition to microscopy, we also used other infor-
mation pertinent to the differentiation of CS from GCM such
as results of imaging studies with either 18-F-
fuorodeoxyglucose positron emission tomography (18FFDG
PET) or computed tomography.
For the review of the 24 cases from the cause-of-death
registry, the slides and histological material available from au-
topsies were re-examined. The written autopsy reports were
scrutinized for observations of other cardiac diseases and
extracardiac organ involvement. The lifetime medical records
of the deceased were studied for their medical history and
any cardiac symptoms and examinations shortly before
death.
The histopathologic re-evaluation of all GCM cases was
made by two pathologists (A.R.-S. and M.I.M.) with
>10 years experience in cardiovascular pathology. Their con-
sensus was needed to convert the diagnosis of GCM to CS in
clinico-pathological meetings with the cardiologists (K.E., J.L.,
and M.K.).
Criteria for reclassification of GCM
The histologic criteria for GCM were identical to the ones
used previously with the addition that the presence of any
myocardial granulomas recognizable with reasonable cer-
tainty, including the immature ones identified with help of
immunohistochemistry, were considered diagnostic of CS.
Furthermore, cases where histologic studies confirmed or
18FFDG PET strongly suggested the presence of extracardiac
sarcoidosis were reclassified as CS even in the absence of
myocardial granulomas.
Ethical approvals
The MIDFIN registry study had the approval of the national
ethical review board (STM/1219/2009). The National Au-
thority for Medicolegal Affairs (4615/06.01.03.01/2016)
and the National Institute for Health and Welfare (THL/
691/5.05.00/2016) approved the study of cases from the
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cause-of-death registry and the review of postmortem au-
topsy material. Our study complies with the Declaration of
Helsinki, and written informed consent was obtained from
each patient alive at the time of recruitment into the
MIDFIN registry study.
Statistical analysis
Statistical analysis was used to compare the cases of GCM
reclassified as CS with the ones maintaining the original diag-
nosis. Baseline characteristics are presented as
mean ± standard deviation or as median (interquartile range)
for continuous variables and as frequencies for categorical
variables. Group comparisons were made using Student’s t-
test, Mann–Whitney U test, or χ2 statistic as appropriate. In
survival analysis, follow-up was calculated from the date of
first medical contact because of symptoms that led to the di-
agnosis of GCM during life or were attributable to GCM in
cases diagnosed at autopsy. Survival analysis was carried
out by the Kaplan–Meier method with the composite of
death from any cause or cardiac transplantation as the out-
come endpoint. Cox regression analysis was used to adjust
for confounding factors when comparing event-free survival
between the diagnostic groups. P values <0.05 were consid-
ered statistically significant. Analyses were performed using
SPSS–24 for Macintosh (SPSS Inc, IL) and Xlstat Lifesciences
(Addinsoft, Paris, France).
Results
The rate and causes of reclassification of giant
cell myocarditis
After re-evaluation of the individual GCM diagnoses, 26 out
of the 49 cases in the MIDFIN registry were reclassified as
CS as were 19 of the 24 cases filed as GCM in the cause-of-
death registry. The main reasons for reclassification are sum-
marized in Figure 1. In 20 cases from the MIDFIN registry and
nine cases from the cause-of-death registry, re-evaluation ex-
posed originally missed myocardial granulomas varying from
occasional well-formed follicular structures to immature
granulomas in different stages of development. With the help
of immunohistochemistry, the immature granulomas were
recognized more confidently. Figure 2 exemplifies a
well-formed granuloma (Figure 2A) and an immature one first
in haematoxylin and eosin (H&E) staining (Figure 2B) and af-
ter immunostaining for CD68 (Figure 2C) and PD-L1 (Figure
2D). Even staining for CD4 positive T helper cells was of some
help whereas CD3 and CD8 positive T cells were scattered
around the myocardium and did not highlight the granulo-
mas. Recognition of GCs and granulomas in the postmortem
myocardium was complicated by frequent tissue autolysis
(Figure 3A). In altogether 11 cases, 10 from the cause-of-
death registry and one from the MIDFIN registry, presence
of extracardiac, and even cardiac granulomas had been cor-
rectly recognized and reported at the autopsy, but the diag-
nosis assigned by the forensic or general pathologist was
GCM. The most common sites for the extracardiac granulo-
mas were mediastinal lymph nodes, lungs, kidneys, and liver
(Figure 3B–D). In two cases transplanted for GCM,
re-evaluation of specimens available from the native hearts
revealed granulomas missed in the original explant study. In
one further posttransplant case, follow-up allograft biopsies
showed recurrence of disease with myocardial granulomas di-
agnostic of CS. Finally, extracardiac findings were the reason
for reclassification in two instances. In one of them, sarcoid
granulomas were found on microscopy of renal tissue sam-
ples while in the other case, with poor-quality original
Figure 1 Flow chart summarizing the study material and the reasons for
reclassification of GCM as CS. Of the 24 cause-of-death registry cases, 10
were reclassified because of originally found but misinterpreted granulo-
mas and nine for myocardial granulomas missed at autopsy. All remaining
reasons pertain to cases from the MIDFIN registry.
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myocardial slides, 18FFDG PET taken at presentation showed
extracardiac inflammatory activity (mediastinal lymph nodes,
lungs) favouring the diagnosis of CS. Altogether 32 of the 45
reclassified cases had isolated CS, that is, no signs of
extracardiac sarcoid granulomas had been recorded either
at autopsy or in whole-body 18FFDG PET.
Comparison between the groups of cardiac
sarcoidosis and giant cell myocarditis resulting
from re-evaluation
Table 1 compares patients’ characteristics, treatment, and
cardiac events between the subgroups of GCM reclassified
as CS and keeping the GCM diagnosis. At presentation, pa-
tients relocated to the CS group were younger, had lower cir-
culating troponin-T and NT-proBNP and were less likely to
have heart failure. As Table 1 shows, altogether 16 patients
reclassified as CS had received GCM-targeted immunosup-
pression including cyclosporine. Impaired renal function (glo-
merular filtration rate < 60mL/min/m2) was observed during
follow-up in six of them with severe renal failure (glomerular
filtration rate < 30 mL/m2/min) being noted in one case. No
malignancies were observed during follow-up, but one case
of recurrent diverticulitis was considered an infectious com-
plication of immunosuppression. In 2019, immunosuppres-
sion for GCM was fully withdrawn in five stable patients
reclassified as CS; no signs of disease relapse have been
noted in any of them over a minimum of 6 months of
follow-up.
Figure 4 shows the transplant-free survival graphs for the
GCM patients reclassified as CS (n = 34) and maintaining the
GCM diagnosis (n = 25); cases with sudden death as the only
presenting manifestation (n = 14) were excluded from the
analysis. The Kaplan–Meier estimate (95% confidence inter-
val) of 1 year transplant-free survival was 82% (70–95%) in
CS and 45% (24–66%) in GCM. At 5 years, the estimate was
46% (28–64%) in CS and 27% (7–47%) in GCM. In a Cox re-
gression analysis with diagnosis, age, and presentation with
heart failure as explanatory factors, CS was an independent
predictor of outcome with a hazard ratio (95% confidence in-
terval) of 0.370 (0.169–0.809, P = 0.013).
Figure 2 (A) Well-formed granulomas (asterix) in the fibrotic cardiac tissue from a CS patient (H&E-staining, original magnification ×25). (B)
Endomyocardial biopsy showing dense lymphocytic infiltrate with pale areas representing immature granulomas (asterix, H&E-staining, original mag-
nification ×10). Immunohistochemical staining for markers of CD68 (macrophages, red) and CD31 (endothelium, brown) (Panel C) and PD-L1 (Panel D)
highlights the granulomas.
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Discussion
The present study, an audit of the cases of GCM diagnosed in
Finland since the late 1980s, was our response to seeing in a
short while several cases of GCM raising suspicion of
misdiagnosed CS. We found that the original GCM diagnoses
appeared to need conversion to CS in more than 60% of
cases, mainly because of the identification of myocardial
granulomas that had originally escaped detection or looked
too equivocal to meet the criteria at that time. In support
of our reclassification, patients relocated to the CS group
had less severe myocardial injury and less heart failure at pre-
sentation than those keeping the GCM diagnosis. They also
had moderately better transplant-free survival. Importantly,
the present work was designed on the premise of CS and
GCM being distinct disease entities. In the end, however,
our findings combined with the earlier literature set us
doubting that concept and reviving the possibility that CS
and GCM instead may represent different degrees of severity
of a single disease.
Role of myocardial granulomas in the
reclassification of GCM
The conspicuously high rate of diagnostic reclassifications be-
cause of previously ‘missed’ myocardial granulomas calls for
explanations. Non-necrotizing myocardial granulomas, ob-
servable as tightly packed and well-demarcated follicular ag-
gregates of epithelioid macrophages, lymphocytes, and
multinuclear GCs, are the histologic hallmark of CS.13–15 They
are thought to trap the causative agents and limit the local in-
flammatory injury.13 Immature granulomas, representing an
earlier stage of development, are looser and less
well-demarcated assemblies of immune cells that may escape
detection on routine microscopy.14,15 In the present work,
Figure 3 Autopsy samples of myocardium (Panel A, H&E staining, original magnification ×20) and lymph node from the same patient (Panel B, H&E
staining, original magnification ×40) demonstrate the difficulties in postmortem studies. Tissue autolysis makes the diagnostic microscopy more chal-
lenging as the GCs (thin arrows) loose nuclei and granulomas (asterix) become less evident. Extracardial granulomas (asterix) seen in the liver (Panel C,
H&E staining, original magnification ×10) and in kidney (Panel D, asterix, H&E staining, original magnification ×20). These can even be confused with
normal autolytic glomeruli of the kidney (Panel D, thick arrows).
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finding myocardial granulomas, whether well-formed or
immature-looking, was an indication to reclassify GCM as
CS. In the original diagnostic studies of our clinical case series,
only unequivocal follicular granulomas were considered diag-
nostic of CS.11,12 Thus, evolving diagnostic criteria constitute
one explanation for the high rate of reclassifications. Another
explanation is the use of ancillary immunohistochemistry that
helped us detect immature granulomas. The third explana-
tion comes from the autopsy series in which even fully
formed myocardial granulomas had escaped detection. Be-
cause of the rarity of CS and GCM forensic and general pa-
thologists encounter them too seldom to gain the
experience needed for their proper recognition and differen-
tiation. GCs and granulomas also lose their nuclear structure
in the early stage of autolysis which complicates their identi-
fication in postmortem examinations.
A crucial point in our analyses is the categorical interpreta-
tion of myocardial granulomas as exclusive of the diagnosis of
GCM. Admittedly, this is an issue short of unanimity among
researchers. Like us here, Davies et al.8 and Litovsky et al.4
have emphasized the absence of granulomas in GCM, and
this view was adopted also in the landmark report by the
Multicenter GCM Study Group in 1997.7 Yet in the subse-
quent work of the same group,6 comparing CS and GCM,
presence of myocardial granulomas was not considered ex-
clusive of the diagnosis of GCM. Cooper and ElAmm16 have
also indicated that poorly formed myocardial granulomas
can be seen in GCM. This variation in the diagnostic
interpretation of granulomas clouds the distinction between
CS and GCM and complicates the comparison of findings from
different studies. It may also explain why, in our series, foren-
sic and general pathologists had frequently diagnosed GCM
even when recognizing granulomas in or outside the heart.
Ultimately, it mirrors the question of whether we are dealing
here with one or two disease entities.
Other causes for reclassification
In a small number of cases reclassification of GCM as CS was
based on the presence of extracardiac findings indicative of
sarcoidosis. We think today that patients with an apparently
typical histology of GCM but non-fulminant clinical picture
should undergo whole-body17F-FDG PET to identify targets
for additional diagnostic biopsies. Exposing extracardiac sar-
coid granulomas could save the patient from overaggressive
treatment. In two cases of GCM, a thorough re-evaluation
of the specimens still available from explanted hearts re-
vealed granulomas diagnostic of CS. This taught us that not
only endomyocardial biopsies but also explant studies are
susceptible of sampling errors because of the sparsity of
granulomas in burnt-out native hearts. In endomyocardial bi-
opsies, the bioptome may not hit the area of inflammation or
misses granulomas even when showing the presence of myo-
carditis. Any granulomas residing deeper in the myocardium
are out of the reach of the bioptome.
Table 1 Patient characteristics and follow-up information by the reclassified groups
CS (N = 45) GCM (N = 28) P value
Age at presentation, year 49 ± 13 58 ± 10 0.003
Female sex, n 32 (71) 19 (68) 0.768
Main presenting manifestation, n
High grade AVB 15 (33) 6 (21) 0.275
Heart failure 9 (20) 13 (46) 0.017
Sustained VT 4 (9) 2 (7) 0.580
Aborted SCD a 1 (2) 1 (4) 1.000
SCD 11 (24) 3 (11) 0.147
Other 5 (11) 3 (11) 0.637
LVEF at presentation, % b 44 ± 15 38 ± 15 0.139
Cardiac troponin T, ng/L c 50 (18–61) 1239 (759–2522) <0.001
NT-proBNP, ng/L d 1710 (985–4611) 5273 (2782–11309) 0.007
Essentials of treatment and outcome events in cases with lifetime disease
presentation
N = 34 N = 25
Implantable cardioverter defibrillator, n 1+7 (50) 13 (52) 0.412
Triple drug immunosupression, n e 16 (47) 14 (56) 0.529
Years of follow-up, median (range) 2.3 (1.1–6.5) 0.5 (0.1–1.6) <0.001
Deaths, n 13 (38) 5 (20)
Heart transplantations, n 7 (21) f 11 (44) g
Data are expressed as mean ± standard deviation, number (%) of cases, or median (interquartile range)
AVB, atrioventricular block; CS, cardiac sarcoidosis; GCM, giant cell myocarditis; LVEF, left ventricular ejection fraction; NT-proBNP,
N-terminal pro-B type natriuretic peptide; SCD, sudden cardiac death; VT, ventricular tachycardia.
aCardiac arrest with successful resuscitation.
bData available in 55 cases.
cData available in 44 cases.
dData available in 43 cases.
eCombination consisting of prednisolone, azathioprine, and cyclosporine.
fOne patient died post-transplantation.
gThree patients died post-transplantation.
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Are cardiac sarcoidosis and giant cell myocarditis
different diseases or different segments of a
single disease spectrum?
At the turn of the millennium, two research groups4,6 re-
ported on comparisons between cases of CS and GCM.
Litovsky et al.4 analysed in retrospect myocardial autopsy
specimens available from eight patients with GCM and seven
patients with CS. The main microscopic discriminators were
granulomas, being fully absent in GCM, and myocyte necro-
sis, which was not seen in CS. Okura et al.,6 in turn, compared
cardiac histopathology and clinical characteristics between 73
cases of GCM and 42 cases of CS collected from 48 centres
worldwide. Although all centres contributed cases of GCM,
the majority, surprisingly, did not have a single case of CS.
There was also a marked racial mismatch between the
groups. In contrast to Litovsky et al.,4 Okura et al.6 reported
that myocardial necrosis and granulomas were present in
both CS and GCM although necrosis was more extensive in
GCM while granulomas were more common in CS. Eosino-
phils and lymphocytes were found in higher numbers in
GCM whereas there was more myocardial fibrosis in CS. The
GCM group had more heart failure at presentation and a
shorter transplant-free survival during follow-up. Although
these works4,6 have been widely cited as establishing the con-
cept of CS and GCM being two unique diseases, both fall
short of constituting firm scientific evidence thereof.
CS and GCM share many features that counter the argu-
ment for fully different diseases. First, T
lymphocyte-mediated inflammation appears crucial in both3–
5 and either condition has an association with thymic
tumours.3,8,17–19 Second, their end-to-end spectrum of car-
diac manifestations is equal, and although rapidly progressive
heart failure is much more common in GCM,3,6 CS can also
cause fulminant heart failure20–22 while a protracted clinical
course, in turn, is possible in GCM.23,24 Third, clinically and
histopathologically typical GCM can coexist with proven
extracardiac sarcoidosis.8,25,26 In the 1950s, Tesluk27 de-
scribed idiopathic GCM as a condition commonly associated
with granulomas outside the heart, and half a century later,
Cooper wrote that 5–10% of his patients with GCM have
granulomas in lymph nodes and liver.3 In their autopsy study
and review of CS, Roberts et al.28 concluded that the cases of
GCM with granulomas outside the heart represent CS and
that it may not be possible to distinguish these conditions
by histologic examination of the heart alone. All in all, the
present findings together with a careful analysis of the earlier
literature set us to question the concept of two unique and
different diseases. We think today that CS and GCM more
likely either are intimately related types, ‘twins’, of T cell
myocarditis or represent different degrees of severity of a
single underlying disease.
Limitations
The main limitation of our work is that the results are specific
to the applied diagnostic criteria. In re-evaluating cases of
GCM, we ignored the clinical case history and focused only
on histopathology. To be precise, recognizing granulomas in
or outside the heart set us to reclassify the case as CS. Had
we used other criteria, like the ones of Okura et al.6 whereby
myocardial granulomas do not exclude GCM if the degree of
necrosis is out of proportion of the degree of granulomatous
inflammation, the results would likely have been different.
Yet it is unknown how ‘out of proportion’ should be defined
in this context. Subjectivity is an unavoidable limitation of mi-
croscopy. It may be the more relevant the smaller histopath-
ologic nuances, like immature granulomas here, are under
scrutiny. We tried to minimize this limitation by relying on
the consensus of two experienced cardiac pathologists work-
ing both independently and in simultaneous microscopy ses-
sions. Although the reclassifications were made by
histopathology, the investigators were not blinded to the clin-
ical data. This is a limitation of the analyses comparing the
Figure 4 Kaplan–Meier graphs for transplant-free survival from onset of
symptoms. The blue line stands for patients keeping the GCM diagnosis
at re-evaluation, the green line representing patients reclassified as CS.
Cases without any lifetime symptoms and follow-up, that is, presenting
with unexpected sudden cardiac death (n = 14), were excluded from
the analysis.
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characteristics and outcomes of the groups arising from the
re-evaluation.
Clinical implications and concluding
remarks
It seems sensible to give up any sharp dichotomy of CS and
GCM in clinical work. Whenever one is suspected, additional
examinations are warranted to expose disease outside the
heart, and the patients should be monitored for signs of
extracardiac involvement during follow-up. Irrespective of
their diagnostic interpretation, myocardial granulomas, and
their recognition, remain important because their presence
implicates better prognosis. To avoid missing granulomas,
thorough microscopy of all available tissue samples is
needed, and the use of immunochemistry may help. More
basic and clinical research is needed to unravel the causes
and mechanisms of CS and GCM and to lay the evidence base
for their proper treatment. Such studies can also be expected
to settle the issue of two unique entities versus one disease
with varying faces.
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